BNF for Children (BNFC) 2018-2019

lPRESCRIBING AND DISPENSING INFORMATIONAvailable as

part of the childhood immunisation schedule from

ImmForm.

lMEDICINAL FORMS

There can be variation in the licensing of different medicines

containing the same drug.

Powder and solvent for solution for injection

▶Menitorix(GlaxoSmithKline UK Ltd)

Menitorix vaccine powder and solvent for solution for injection 0. 5 ml

vials| 1 vialP£ 37. 76

eiiiiF 788

Meningococcal group B vaccine (rDNA,

component, adsorbed) 19-Oct-2017

lINDICATIONS AND DOSE

BEXSERO®

Immunisation againstNeisseria meningitidis, primary

immunisation

▶BY DEEP INTRAMUSCULAR INJECTION

▶Child 2 months: 0. 5 mL for 1 dose, injected preferably

into deltoid region (or anterolateral thigh in infants),

for information about the use of paracetamol for

prophylaxis of post-immunisation pyrexia, see

paracetamol p. 271.

▶Child 4 months: 0. 5 mL for 1 dose, injected preferably

into deltoid region (or anterolateral thigh in infants),

for information about the use of paracetamol for

prophylaxis of post-immunisation pyrexia, see

paracetamol p. 271.

Immunisation againstNeisseria meningitidis, primary

immunisation booster dose

▶BY DEEP INTRAMUSCULAR INJECTION

▶Child 12–23 months: 0. 5 mL for 1 dose, injected

preferably into deltoid region (or anterolateral thigh in

infants)

Immunisation againstNeisseria meningitidis, primary

immunisation (in unimmunised patients)

▶BY DEEP INTRAMUSCULAR INJECTION

▶Child 6–11 months: 0. 5 mL for 2 doses, separated by an

interval of at least 2 months; booster dose of 0. 5 mL

given between 1 – 2 years of age and at least 2 months

after completion of primary immunisation, injected

preferably into deltoid region (or anterolateral thigh in

infants)

▶Child 12–23 months: 0. 5 mL for 2 doses, separated by an

interval of at least 2 months; booster dose of 0. 5 mL

given 12 – 24 months after completion of primary

immunisation, injected preferably into deltoid region

(or anterolateral thigh in infants)

▶Child 2–10 years: 0. 5 mL for 2 doses, separated by an

interval of at least 2 months. Injected preferably into

deltoid region (or anterolateral thigh in infants)

▶Child 11–17 years: 0. 5 mL for 2 doses, separated by an

interval of at least 1 month. Injected preferably into

deltoid region

TRUMENBA®

Immunisation againstNeisseria meningitidis, primary

immunisation

▶BY INTRAMUSCULAR INJECTION

▶Child 10–17 years: 0. 5 mL for 2 doses, separated by an

interval of 6 months, alternatively 0. 5 mL for 2 doses,

separated by an interval of at least 1 month, followed

by 0. 5 mL as a third dose, given at least 4 months after

the second dose, injected preferably into deltoid

region, a booster dose should be considered for

individuals at continued risk—consult product

literature

lSIDE-EFFECTS

▶Common or very commonCrying abnormal.drowsiness.

eating disorder

▶UncommonEczema.seizures.vascular disorders

▶Frequency not knownExtensive swelling of vaccinated limb

.hypotonic-hyporesponsiveness episode

lMEDICINAL FORMS

There can be variation in the licensing of different medicines

containing the same drug.

Suspension for injection

EXCIPIENTS:May contain Kanamycin

▶Bexsero(GlaxoSmithKline UK Ltd)A

Bexsero vaccine suspension for injection 0. 5 ml pre-filled syringes|

1 pre-filled disposable injectionP£ 75. 00

▶Trumenba(Pfizer Ltd)A

Trumenba vaccine suspension for injection 0. 5 ml pre-filled syringes|

1 pre-filled disposable injectionP£ 75. 00

eiiiiF 788

Meningococcal group C vaccine

lINDICATIONS AND DOSE

Patients with confirmed serogroup C disease (who have

previously been immunised)

▶BY INTRAMUSCULAR INJECTION

▶Child 1–17 years: 0. 5 mL for 1 dose, dose to be given

before discharge from hospital

lSIDE-EFFECTS

▶Common or very commonAnxiety.cough.crying.

drowsiness.gastrointestinal discomfort.hyperhidrosis.

increased risk of infection

▶UncommonChills.eyelid oedema.flushing.joint stiffness

▶Rare or very rareCirculatory collapse.influenza like

illness

▶Frequency not knownAngioedema.apnoea.asthenia.

dyspnoea.hypotonic-hyporesponsiveness episode.

immune thrombocytopenic purpura.meningism (but no

evidence that vaccine causes meningococcal C meningitis)

.musculoskeletal stiffness.nasal congestion.oedema.

pain.respiratory disorders.seizures.sensation abnormal.

sleep disorders.Stevens-Johnson syndrome.syncope

lPRESCRIBING AND DISPENSING INFORMATIONAvailable as

part of childhood immunisation schedule from

http://www.immform.dh.gov.uk.

lMEDICINAL FORMS

There can be variation in the licensing of different medicines

containing the same drug.

Suspension for injection

▶NeisVac-C(Pfizer Ltd)

NeisVac-C vaccine suspension for injection 0. 5 ml pre-filled syringes|

10 pre-filled disposable injectionP£ 187. 50

eiiiiF 788

Meningococcal groups A with C and

W135 and Y vaccine

lINDICATIONS AND DOSE

MENVEO®

Primary immunisation againstNeisseria meningitidis

▶BY INTRAMUSCULAR INJECTION

▶Child 13–15 years: 0. 5 mL for 1 dose, dose preferably

injected into deltoid region

Immunisation againstNeisseria meningitidisin an

unimmunised patient

▶BY INTRAMUSCULAR INJECTION

▶Child 10–17 years: 0. 5 mL for 1 dose, booster dose is not

required

792 Vaccination BNFC 2018 – 2019

Vaccines

14